Free Trial
NASDAQ:PHXM

PHAXIAM Therapeutics (PHXM) Stock Price, News & Analysis

PHAXIAM Therapeutics logo
$3.10 0.00 (0.00%)
As of 07/21/2025

About PHAXIAM Therapeutics Stock (NASDAQ:PHXM)

Key Stats

Today's Range
$3.10
$3.10
50-Day Range
$3.10
$3.10
52-Week Range
$2.50
$13.00
Volume
N/A
Average Volume
2,472 shs
Market Capitalization
$10.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive PHXM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PHAXIAM Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PHXM Stock News Headlines

The Private Market Surge Is Coming in 2025
The most lucrative investment opportunities are reserved for a select category of investor. They're private. They're quiet. And they're often available exclusively to accredited investors operating outside the noise of the public markets. We're talking about off-market placements, early venture deals, private credit, and pre-IPO shares—the kind of plays that can generate outsized gains before Wall Street catches wind. Here's the reality: having access is only the beginning. These deals can be opaque, rushed, and filled with hidden risk. That's why we created something exclusively for investors like you—the 2025 Accredited Investor Playbook.
See More Headlines

PHXM Stock Analysis - Frequently Asked Questions

PHAXIAM Therapeutics' stock was trading at $3.10 on January 1st, 2025. Since then, PHXM stock has increased by 0.0% and is now trading at $3.10.

PHAXIAM Therapeutics's stock reverse split on Wednesday, September 20th 2023.The 1-10 reverse split was announced on Wednesday, September 20th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of PHXM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that PHAXIAM Therapeutics investors own include Salesforce (CRM), AbbVie (ABBV), Bank of America (BAC), Chevron (CVX), Merck & Co., Inc. (MRK), The PNC Financial Services Group (PNC) and AGCO (AGCO).

Company Calendar

Today
7/25/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PHXM
CIK
1624422
Employees
49
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.23
Current Ratio
1.78
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.98 per share
Price / Book
0.39

Miscellaneous

Outstanding Shares
3,412,000
Free Float
3,346,000
Market Cap
$10.58 million
Optionable
No Data
Beta
2.35
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:PHXM) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners